Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis.

Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY.

Am J Clin Oncol. 2019 Jun 3. doi: 10.1097/COC.0000000000000560. [Epub ahead of print]

PMID:
31166209
2.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS.

JAMA Oncol. 2019 May 30. doi: 10.1001/jamaoncol.2019.0892. [Epub ahead of print]

PMID:
31145418
3.

A Phase 1b/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC.

Clin Cancer Res. 2019 May 29. pii: clincanres.4010.2018. doi: 10.1158/1078-0432.CCR-18-4010. [Epub ahead of print]

PMID:
31142504
4.

TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leshchiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.

Cancer Discov. 2019 May 20. pii: CD-19-0182. doi: 10.1158/2159-8290.CD-19-0182. [Epub ahead of print]

PMID:
31109923
5.

Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?

Franses JW, Hong TS, Zhu AX.

Lancet Gastroenterol Hepatol. 2019 May 17. pii: S2468-1253(19)30148-7. doi: 10.1016/S2468-1253(19)30148-7. [Epub ahead of print] No abstract available.

PMID:
31109809
6.

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.

Feng M, Jin JQ, Xia L, Xiao T, Mei S, Wang X, Huang X, Chen J, Liu M, Chen C, Rafi S, Zhu AX, Feng YX, Zhu D.

Sci Adv. 2019 May 8;5(5):eaau5240. doi: 10.1126/sciadv.aau5240. eCollection 2019 May.

7.

Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.

Goyal L, Qadan M, Zhu AX.

JAMA Oncol. 2019 May 9. doi: 10.1001/jamaoncol.2019.0249. [Epub ahead of print] No abstract available.

PMID:
31070694
8.

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX.

Future Oncol. 2019 Jun;15(16):1811-1822. doi: 10.2217/fon-2019-0097. Epub 2019 Apr 10.

9.

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein.

Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M.

Lancet Oncol. 2019 Apr;20(4):e191. doi: 10.1016/S1470-2045(19)30165-2. No abstract available.

PMID:
30942178
10.

Has PD-1 MET Its Match in Hepatocellular Carcinoma?

Franses JW, Zhu AX.

Gastroenterology. 2019 May;156(6):1563-1565. doi: 10.1053/j.gastro.2019.03.029. Epub 2019 Mar 26. No abstract available.

PMID:
30926349
11.

Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection.

Lee GC, Ferrone CR, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Zhu AX, Hong TS, Qadan M.

Am J Surg. 2019 Mar 4. pii: S0002-9610(18)31353-9. doi: 10.1016/j.amjsurg.2019.02.036. [Epub ahead of print]

PMID:
30871788
12.

Assessing deforestation susceptibility to forest ecosystem in Rudraprayag district, India using fragmentation approach and frequency ratio model.

Sahana M, Hong H, Sajjad H, Liu J, Zhu AX.

Sci Total Environ. 2018 Jun 15;627:1264-1275. doi: 10.1016/j.scitotenv.2018.01.290. Epub 2018 Feb 7.

PMID:
30857091
13.

Long-term variation of phytoplankton biomass and physiology in Taihu lake as observed via MODIS satellite.

Huang C, Zhang Y, Huang T, Yang H, Li Y, Zhang Z, He M, Hu Z, Song T, Zhu AX.

Water Res. 2019 Apr 15;153:187-199. doi: 10.1016/j.watres.2019.01.017. Epub 2019 Jan 25.

PMID:
30711794
14.

Vulnerability of cotton subjected to hail damage.

Yue Y, Zhou L, Zhu AX, Ye X.

PLoS One. 2019 Jan 30;14(1):e0210787. doi: 10.1371/journal.pone.0210787. eCollection 2019.

15.

Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.

Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, Allen JN, Blaszkowsky LS, Ryan DP, Ferrone CR, Tanabe KK, Qadan M, Crane CH, Koay EJ, Eyler C, DeLaney TF, Zhu AX, Wo JY, Grassberger C, Hong TS.

Int J Radiat Oncol Biol Phys. 2019 Jan 23. pii: S0360-3016(19)30158-0. doi: 10.1016/j.ijrobp.2019.01.076. [Epub ahead of print]

PMID:
30684667
16.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators.

Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.

PMID:
30665869
17.

Current status and evolving treatment for primary liver cancers.

Zhu AX, Aloia TA.

Chin Clin Oncol. 2018 Oct;7(5):47. doi: 10.21037/cco.2018.10.05. No abstract available.

18.

Coordination Network That Reversibly Switches between Two Nonporous Polymorphs and a High Surface Area Porous Phase.

Zhu AX, Yang QY, Kumar A, Crowley C, Mukherjee S, Chen KJ, Wang SQ, O Nolan D, Shivanna M, Zaworotko MJ.

J Am Chem Soc. 2018 Nov 21;140(46):15572-15576. doi: 10.1021/jacs.8b08642. Epub 2018 Nov 9.

PMID:
30395458
19.

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.

Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG.

NPJ Precis Oncol. 2018 Oct 18;2:22. doi: 10.1038/s41698-018-0065-y. eCollection 2018.

20.

Radiotherapy for Biliary Tract Cancers.

Keane FK, Zhu AX, Hong TS.

Semin Radiat Oncol. 2018 Oct;28(4):342-350. doi: 10.1016/j.semradonc.2018.06.003. Review.

PMID:
30309644
21.

Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy.

Keane FK, Hong TS, Zhu AX.

Semin Radiat Oncol. 2018 Oct;28(4):332-341. doi: 10.1016/j.semradonc.2018.06.006. Review.

PMID:
30309643
22.

Global sensitivity analysis of the APSIM-Oryza rice growth model under different environmental conditions.

Liu J, Liu Z, Zhu AX, Shen F, Lei Q, Duan Z.

Sci Total Environ. 2019 Feb 15;651(Pt 1):953-968. doi: 10.1016/j.scitotenv.2018.09.254. Epub 2018 Sep 20.

PMID:
30257234
23.

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX.

Hepatology. 2019 Apr;69(4):1803-1815. doi: 10.1002/hep.30289. Epub 2019 Mar 25. Review.

PMID:
30251463
24.

Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation?

Costentin CE, Bababekov YJ, Zhu AX, Yeh H.

Hepatology. 2019 Mar;69(3):1324-1336. doi: 10.1002/hep.30278. Review.

PMID:
30229978
25.

Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.

Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, Ting DT.

Gastroenterology. 2018 Dec;155(6):2016-2018.e11. doi: 10.1053/j.gastro.2018.09.020. Epub 2018 Sep 13. No abstract available.

PMID:
30218669
26.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

PMID:
30190369
27.

Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX.

Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. No abstract available.

PMID:
29970352
28.

Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis.

McDuff SGR, Remillard KA, Zheng H, Raldow AC, Wo JY, Eyler CE, Drapek LC, Goyal L, Blaszkowsky LS, Clark JW, Allen JN, Parikh AR, Ryan DP, Ferrone CR, Tanabe KK, Wolfgang JA, Zhu AX, Hong TS.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):414-421. doi: 10.1016/j.prro.2018.04.012. Epub 2018 Apr 26.

PMID:
29937235
29.

Landslide susceptibility modelling using GIS-based machine learning techniques for Chongren County, Jiangxi Province, China.

Chen W, Peng J, Hong H, Shahabi H, Pradhan B, Liu J, Zhu AX, Pei X, Duan Z.

Sci Total Environ. 2018 Jun 1;626:1121-1135. doi: 10.1016/j.scitotenv.2018.01.124. Epub 2018 Feb 19.

PMID:
29898519
30.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.

Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.

PMID:
29875066
31.

Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.

Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1222-1225. doi: 10.1016/j.ijrobp.2018.04.026. Epub 2018 Apr 17.

PMID:
29859792
32.

Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.

Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S.

Cardiovasc Intervent Radiol. 2018 Nov;41(11):1799-1802. doi: 10.1007/s00270-018-1993-1. Epub 2018 May 29.

PMID:
29845347
33.

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.

Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX.

Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29.

34.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.

Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS.

JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.

35.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

36.

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Weekes CD, Clark JW, Zhu AX.

Lancet Oncol. 2018 May;19(5):591-592. doi: 10.1016/S1470-2045(18)30249-3. Epub 2018 Apr 3. No abstract available.

PMID:
29625880
37.

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK.

Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913. No abstract available.

PMID:
29624699
38.

Applying genetic algorithms to set the optimal combination of forest fire related variables and model forest fire susceptibility based on data mining models. The case of Dayu County, China.

Hong H, Tsangaratos P, Ilia I, Liu J, Zhu AX, Xu C.

Sci Total Environ. 2018 Jul 15;630:1044-1056. doi: 10.1016/j.scitotenv.2018.02.278. Epub 2018 Mar 7.

PMID:
29554726
39.

Hepatocellular Carcinoma With Portal Venous Invasion: Radiating New Hope?

Farsad K, Costentin CE, Zhu AX.

JAMA Oncol. 2018 May 1;4(5):669-670. doi: 10.1001/jamaoncol.2018.0007. No abstract available.

PMID:
29543953
40.

Application of fuzzy weight of evidence and data mining techniques in construction of flood susceptibility map of Poyang County, China.

Hong H, Tsangaratos P, Ilia I, Liu J, Zhu AX, Chen W.

Sci Total Environ. 2018 Jun 1;625:575-588. doi: 10.1016/j.scitotenv.2017.12.256. Epub 2017 Dec 30.

PMID:
29291572
41.

Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy.

Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX.

Liver Cancer. 2017 Nov;6(4):360-374. doi: 10.1159/000481315. Epub 2017 Oct 19. Review.

42.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

43.

Carbon and nitrogen burial in a plateau lake during eutrophication and phytoplankton blooms.

Huang C, Zhang L, Li Y, Lin C, Huang T, Zhang M, Zhu AX, Yang H, Wang X.

Sci Total Environ. 2018 Mar;616-617:296-304. doi: 10.1016/j.scitotenv.2017.10.320. Epub 2017 Nov 6.

PMID:
29121578
44.

Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?

Aoki S, Cobbold M, Zhu AX, Duda DG.

Hepatology. 2018 Mar;67(3):826-828. doi: 10.1002/hep.29617. Epub 2018 Jan 30. No abstract available.

45.

Flood susceptibility assessment in Hengfeng area coupling adaptive neuro-fuzzy inference system with genetic algorithm and differential evolution.

Hong H, Panahi M, Shirzadi A, Ma T, Liu J, Zhu AX, Chen W, Kougias I, Kazakis N.

Sci Total Environ. 2018 Apr 15;621:1124-1141. doi: 10.1016/j.scitotenv.2017.10.114. Epub 2017 Nov 1.

PMID:
29074239
46.

Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer.

Pretz JL, Blake MA, Killoran JH, Mamon HJ, Wo JY, Zhu AX, Hong TS.

Pract Radiat Oncol. 2018 May - Jun;8(3):179-184. doi: 10.1016/j.prro.2017.09.008. Epub 2017 Sep 18.

PMID:
29042120
47.

Recent developments in systemic therapy for hepatocellular carcinoma.

Zhu AX.

Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):7-13. No abstract available.

PMID:
29036037
48.

The treatment path in hepatocellular carcinoma.

El-Serag HB, Zhu AX, Johnson MS.

Clin Adv Hematol Oncol. 2017 Aug;15 Suppl 9(8):1-20.

PMID:
29036035
49.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
50.

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I.

Ann Oncol. 2017 Dec 1;28(12):2932-2942. doi: 10.1093/annonc/mdx514. Review.

Supplemental Content

Support Center